Article
Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.
Drug metabolism and disposition: the biological fate of chemicals - 1 Apr 2015
Lee Caroline A, O'Connor Meeghan A, Ritchie Tasha K, Galetin Aleksandra, Cook Jack A, Ragueneau-Majlessi Isabelle, Ellens Harma, Feng Bo, Taub Mitchell E, Paine Mary F, Polli Joseph W, Ware Joseph A, Zamek-Gliszczynski Maciej J
Abstract excerpt
Breast cancer resistance protein (BCRP; ABCG2) limits intestinal absorption of low-permeability substrate drugs and mediates biliary excretion of drugs and metabolites. Based on clinical evidence of BCRP-mediated drug-drug interactions (DDIs) and the c.421C>A functional polymorphism affecting drug efficacy and safety, both the US Food and Drug Administration and European Medicines Agency recommend preclinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.